MA37821A1 - Utilisation d'inhibiteurs de vegfr-3 destinés au traitement du carcinome hépatocellulaire - Google Patents

Utilisation d'inhibiteurs de vegfr-3 destinés au traitement du carcinome hépatocellulaire

Info

Publication number
MA37821A1
MA37821A1 MA37821A MA37821A MA37821A1 MA 37821 A1 MA37821 A1 MA 37821A1 MA 37821 A MA37821 A MA 37821A MA 37821 A MA37821 A MA 37821A MA 37821 A1 MA37821 A1 MA 37821A1
Authority
MA
Morocco
Prior art keywords
inhibitors
treatment
hepatocellular carcinoma
vegfr
growth factor
Prior art date
Application number
MA37821A
Other languages
English (en)
Inventor
Antoine Alam
Isabelle Blanc
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA37821A1 publication Critical patent/MA37821A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation d'inhibiteurs du récepteur 3 du facteur de croissance endothéliale vasculaire, destinés au traitement du carcinome hépatocellulaire.
MA37821A 2012-07-17 2013-07-16 Utilisation d'inhibiteurs de vegfr-3 destinés au traitement du carcinome hépatocellulaire MA37821A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305866 2012-07-17
PCT/EP2013/065029 WO2014012942A1 (fr) 2012-07-17 2013-07-16 Utilisation d'inhibiteurs de vegfr-3 destinés au traitement du carcinome hépatocellulaire

Publications (1)

Publication Number Publication Date
MA37821A1 true MA37821A1 (fr) 2018-02-28

Family

ID=49948312

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37821A MA37821A1 (fr) 2012-07-17 2013-07-16 Utilisation d'inhibiteurs de vegfr-3 destinés au traitement du carcinome hépatocellulaire

Country Status (31)

Country Link
US (1) US9376432B2 (fr)
EP (1) EP2874625B1 (fr)
JP (1) JP6226981B2 (fr)
KR (1) KR102068860B1 (fr)
CN (1) CN104602691B (fr)
AU (1) AU2013292054B2 (fr)
BR (1) BR112015000942A2 (fr)
CA (1) CA2878987C (fr)
CL (1) CL2015000115A1 (fr)
CR (1) CR20150029A (fr)
CY (1) CY1119415T1 (fr)
DK (1) DK2874625T3 (fr)
EA (1) EA027982B1 (fr)
ES (1) ES2635105T3 (fr)
HK (1) HK1206257A1 (fr)
HR (1) HRP20171227T1 (fr)
HU (1) HUE035712T2 (fr)
IL (1) IL236718A (fr)
LT (1) LT2874625T (fr)
MA (1) MA37821A1 (fr)
MX (1) MX367402B (fr)
PH (1) PH12015500094A1 (fr)
PL (1) PL2874625T3 (fr)
PT (1) PT2874625T (fr)
RS (1) RS56178B1 (fr)
SG (1) SG11201500156SA (fr)
SI (1) SI2874625T1 (fr)
TN (1) TN2015000021A1 (fr)
TW (1) TW201406759A (fr)
WO (1) WO2014012942A1 (fr)
ZA (1) ZA201500182B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2524915A1 (fr) * 2011-05-20 2012-11-21 Sanofi Dérivés de 2-amino-3-(imidazol-2-yl)-pyridin-4-one et leur utilisation en tant qu'inhibiteurs de kinase du récepteur VEGF
WO2014026242A1 (fr) 2012-08-17 2014-02-20 Cancer Therapeutics Crc Pty Limited Inhibiteurs de vegfr3
US9238644B2 (en) 2012-08-17 2016-01-19 Cancer Therapeutics Crc Pty Limited VEGFR3 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2760456B1 (fr) * 1997-03-05 2000-05-12 Sanofi Sa Procede de preparation de derives de 2-thienyl-ethylamine
US5994367A (en) 1997-03-07 1999-11-30 The University Of North Carolina At Chapel Hill Method for treating tumors using 2-aryl-naphthyridin-4-ones
CN1191252C (zh) * 2003-08-11 2005-03-02 中国药科大学 3－位取代的喹诺酮衍生物及其在药学上的应用
AU2004288709B2 (en) * 2003-11-07 2011-01-06 Novartis Vaccines And Diagnostics, Inc. Methods for synthesizing quinolinone compounds
CN1325494C (zh) * 2005-08-18 2007-07-11 中国药科大学 3－位取代的萘啶酮类化合物及其制备方法和在制药中的应用
KR100744826B1 (ko) * 2006-04-05 2007-08-01 한국화학연구원 이미다졸기가 치환된 퀴놀리논 유도체
FR2917412B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
WO2009053799A1 (fr) * 2007-10-24 2009-04-30 Glenmark Pharmaceuticals, S.A. Nouveaux ligands du récepteur cannobinoïde, compositions pharmaceutiques les contenant et leur procédé de préparation
FR2933701A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
FR2933700B1 (fr) * 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
WO2010073078A2 (fr) 2008-12-22 2010-07-01 Orchid Research Laboratories Ltd. Composés hétérocycliques comme inhibiteurs de hdac
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EP2524915A1 (fr) * 2011-05-20 2012-11-21 Sanofi Dérivés de 2-amino-3-(imidazol-2-yl)-pyridin-4-one et leur utilisation en tant qu'inhibiteurs de kinase du récepteur VEGF

Also Published As

Publication number Publication date
LT2874625T (lt) 2017-08-25
BR112015000942A2 (pt) 2017-06-27
EP2874625B1 (fr) 2017-05-17
CL2015000115A1 (es) 2015-05-04
WO2014012942A1 (fr) 2014-01-23
HUE035712T2 (en) 2018-05-28
CA2878987C (fr) 2020-07-21
KR102068860B1 (ko) 2020-01-21
ES2635105T3 (es) 2017-10-02
US20150183780A1 (en) 2015-07-02
EA201590229A1 (ru) 2015-05-29
HK1206257A1 (en) 2016-01-08
HRP20171227T1 (hr) 2017-10-20
PH12015500094A1 (en) 2015-03-02
MX367402B (es) 2019-08-20
RS56178B1 (sr) 2017-11-30
CY1119415T1 (el) 2018-03-07
TN2015000021A1 (en) 2016-06-29
DK2874625T3 (en) 2017-09-11
TW201406759A (zh) 2014-02-16
IL236718A (en) 2017-11-30
PL2874625T3 (pl) 2017-10-31
CR20150029A (es) 2015-04-06
EP2874625A1 (fr) 2015-05-27
AU2013292054A1 (en) 2015-02-05
CN104602691A (zh) 2015-05-06
SI2874625T1 (sl) 2017-10-30
CA2878987A1 (fr) 2014-01-23
JP6226981B2 (ja) 2017-11-08
US9376432B2 (en) 2016-06-28
CN104602691B (zh) 2016-12-28
MX2015000797A (es) 2015-08-13
ZA201500182B (en) 2015-12-23
EA027982B1 (ru) 2017-09-29
KR20150036401A (ko) 2015-04-07
IL236718A0 (en) 2015-02-26
AU2013292054B2 (en) 2017-08-03
PT2874625T (pt) 2017-08-16
JP2015522598A (ja) 2015-08-06
SG11201500156SA (en) 2015-02-27

Similar Documents

Publication Publication Date Title
PH12016500358A1 (en) Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
MD3371190T2 (ro) Compuși heterociclici ca inhibitori PI3K-gamma
EA201500362A1 (ru) Ингибиторы rho-киназы
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
MA35660B1 (fr) Inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
EA201200999A1 (ru) Способы лечения рака молочной железы
EA201171367A1 (ru) Винилиндазолильные соединения
MA37506B1 (fr) Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21
EA201492056A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
UY33931A (es) Agentes de union biespecificos
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
MX2015006859A (es) Anticuerpos anti-vegf y sus usos.
EA201590962A1 (ru) Новые соединения
EA201491303A1 (ru) Конденсированные тетра- или пентациклические дигидродиазепинокарбазолоны в качестве ингибиторов parps
EA201590272A1 (ru) Пероральные дозированные формы для модифицированного высвобождения, содержащие руксолитиниб
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
EA201501123A8 (ru) Новые (циано-диметил-метил)-изоксазолы и -[1,3,4]тиадиазолы
MA37821A1 (fr) Utilisation d'inhibiteurs de vegfr-3 destinés au traitement du carcinome hépatocellulaire
EA201390117A1 (ru) Композиция антител к vegfr-3
MA39126B1 (fr) Synthèse d'enantiomère de progestérone et d'intermédiaires de celui-ci
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
MX354501B (es) Ingrediente perfumante de la familia galbano.